Table 2.
Clinical trials targeting EBV in malignancy.
| Category | Intervention | Drug class | Indication | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
| Lytic Induction | VRx-3996 Valganciclovir | HDACi Antiviral | R/R EBV+ lymphomas | 1b/2 | Recruiting | NCT03397706 |
| Doxorubicin + MTX Zidovudine + Hydroxyurea | Cytotoxic Antiviral Antimetabolite | R/R EBV+ lymphomas PTLD | II | Completed | NCT01964755 | |
| LBH589 RAD001 | HDACi mTOR inhibitor | NPC, EBV+ lymphomas, any EBV+ solid tumor | 1b/2 | Active, not recruiting | NCT01341834 | |
| Epigenetic manipulation | Vorinostat Azacitadine | HDACi Hypomethylator | NPC, Extranodal nasal NK/T cell lymphoma | 1 | Active, not recruiting | NCT00336063 |
| CTL | GRALE CTL | LMP, BARF1, EBNA1 | EBV+ Lymphomas T/NK LPD CAEBV | 1 | Recruiting | NCT01555892 |
| LMP1/2 CTL | LMP1/2 | EBV+ Lymphomas T/NK LPD CAEBV Leiomysarcoma | 1 | Recruiting | NCT01956084 | |
| MABEL CTL | LMP, BARF-1, EBNA1 | EBV+ Lymphomas T/NK LPD CAEBV | 1 | Recruiting | NCT02287311 | |
| PBTLs and EBV-CTLs | CD19-CD28 EBV-specific | R/R low or int grade B-cell lymphoma or B-CLL | 1 | Active, not recruiting | NCT00709033 | |
| CMD-003 | EBV-specific | EBV+ Extranodal NK/T-cell lymphoma | 2 | Recruiting | NCT01948180 |
CAEBV, chronic active epstein-barr virus; CTL, cytotoxic T-lymphocyte; EBV, Epstein-Barr virus; HDACi, histone deacetylase inhibitor; LPD, lymphoproliferative disease; MTX, methotrexate; NPC, nasopharyngeal caricinoma; R/R, relpase/refractory.